ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2293

Anti-Citrullinated Peptide/Protein Antibody Specificities and Subclinical Synovitis In Palindromic Rheumatism: Towards a Better Understanding Of The Relationship With Rheumatoid Arthritis

Sonia Cabrera-Villalba1, Julio Ramirez1, Georgina Salvador2, Virginia Ruiz-Esquide3, M. Victoria Hernández4, José Inciarte5, Celia Saura1, J. D. Cañete1 and Raimon Sanmarti3, 1Rheumatology, Hospital Clinic, Barcelona, Spain, 2Rheumatology Unit., Hospital Mutua de Terrassa. Barcelona, Barcelona, Spain, 3Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 4Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, 5Arthritis Unit. Rheumatology Service, Hospital Clinic of Barcelona, Barcelona, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, palindromic rheumatism, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Palindromic rheumatism (PR) may evolve to rheumatoid arthritis (RA), especially in anti-citrullinated peptide/protein antibody (ACPA) positive patients, although many do not evolve to RA after long-term follow-up. It is unclear whether ACPA-positive patients have more subclinical synovitis during the intercritical phase and whether this is a risk factor for progression to RA. There are no data on different ACPA specificities in PR compared with RA

Objectives:To analyze differences in the presence of subclinical synovitis in PR patients according to ACPA status and determine whether fine specificities of citrullinated peptides differ between PR and RA.

Methods: Patients with pure PR (*Guerne et al criteria) with no progression to chronic rheumatic disease at study entry were included. Clinical, demographic, serological and therapeutic variables were collected. Subclinical synovitis (grade≥ 2 synovial hyperplasia plus Doppler signal) in the intercritical period was analyzed by ultrasound of both hands. ACPA specificities were assayed by home-made ELISA tests using chimeric fibrin/filaggrin (CFFCP1), fibrin/vimentin (CFVCP), and vimentin/fibrin (CVFCP) citrullinated chimeric synthetic peptides in pure PR patients who were positive for commercial CCP2 tests: results were compared with controls with established RA (1987 ACR criteria)

Results: Fifty-seven patients (64.9% female, mean age 51.6±11.2 years and mean disease duration 11.9±10.5 years) with pure PR were included: 39 (68.4%) were ACPA+ (CCP2 test). No significant clinical differences were observed between ACPA+ and ACPA- patients except for a shorter duration of attacks and greater DMARD use (mainly hydroxychloroquine) in ACPA+ patients. RF was most-frequently found in ACPA positive patients. Subclinical synovitis by ultrasound was observed in 16 patients (28.1%), most-frequently in the metacarpal joints and wrists, without significant differences between ACPA+  and ACPA+ PR patients (30.8 vs. 22.2% p=0.51).

Citrullinated peptide specificities did not significantly differ between CCP2+ PR patients (n=39) and control patients (n=39) with established CCP2+ RA (66.7% female, mean disease duration 7.2±4.4 years), although there was a trend to a higher number of specificities and a higher titer of ACPAS in RA patients (Table 1)

Table 1 Frequency of citrullinated peptide specificities in CCP2-positive PR and RA patients.

PR-CCP2 positive

n=39

RA-CCP2 positive

n=39

p value
CCP2 levels(IU/L)
467.72±513.6 761.74 ±595.7 0.09
CFFCP1 n (%) 29 (74.4%) 35 (89.7%) 0.24
CFVCP n (%) 24 (61.5%) 26 (66.7%) 0.6
CVFCP n (%) 29 (74.4%) 34 (87.2%) 0.43
CFFCP1 levels (ODU) 1.01±0.97 1.25±0.88 0.24
CFVCP levels (ODU) 0.59±0.54 0.65±0.60 0.25
CVFCP levels (ODU) 0.82±0.80 0.89±0.66 0.24
≥2 Specificities 28 (71.7%) 35 (89.7%) 0.2
3 Specificities 23 (59%) 25 (64.1%)

0.7

ODW: optic density units

Conclusion: ACPA are frequently found in patients with PR. Most PR patients do not have subclinical synovitis (by ultrasound), which is not associated with ACPA status, in the intercritical period. No significant differences in the different specificities of ACPAS were observed between PR and RA, suggesting that chronic PR might be considered an abortive form of RA


Disclosure:

S. Cabrera-Villalba,
None;

J. Ramirez,
None;

G. Salvador,
None;

V. Ruiz-Esquide,
None;

M. V. Hernández,
None;

J. Inciarte,
None;

C. Saura,
None;

J. D. Cañete,
None;

R. Sanmarti,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-peptideprotein-antibody-specificities-and-subclinical-synovitis-in-palindromic-rheumatism-towards-a-better-understanding-of-the-relationship-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.